{"entity":{"id":"robin-jones","kind":"person","name":"Robin L. Jones","aka":[],"tldr":"London sarcoma specialist who led TAPPAS, the trial that tested the anti-angiogenic protein TRC105 with pazopanib in angiosarcoma, and who has led many international sarcoma trials.","summary":"Robin Jones heads the sarcoma unit at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2022 Journal of Clinical Oncology report of TAPPAS, the phase 3 trial in which adding the endoglin antibody carotuximab (TRC105) to pazopanib did not improve progression-free survival in advanced angiosarcoma. He has been a lead investigator on trials of trabectedin, eribulin and afami-cel in sarcoma.","asOf":"2026-09-18","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["angiosarcoma","vascular-tumours","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":["tappas"],"people":[],"bottlenecks":[],"keyPapers":["paper-esmo-sts-guideline-gronchi-ann-oncol-2021","paper-robin-jones-ann-oncol-2018","paper-robin-jones-lancet-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Sarcoma Unit, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Soft tissue sarcoma","Angiosarcoma","Sarcoma drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jones%5BAuthor%5D"}],"papers":[{"title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","journal":"Annals of Oncology","year":2021,"url":"https://doi.org/10.1016/j.annonc.2021.07.006","doi":"10.1016/j.annonc.2021.07.006","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 742 citations on Europe PMC."},{"title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2018,"url":"https://doi.org/10.1093/annonc/mdy096","doi":"10.1093/annonc/mdy096","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 471 citations on Europe PMC."},{"title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","journal":"The Lancet","year":2016,"url":"https://doi.org/10.1016/s0140-6736(16)30587-6","doi":"10.1016/s0140-6736(16)30587-6","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 452 citations on Europe PMC."}],"orcid":"0000-0003-4173-3844"},"route":"/people/robin-jones/","neighbours":{"cancer":[{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/"}],"institution":[{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"trial":[{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/"}],"paper":[{"id":"paper-robin-jones-lancet-2016","kind":"paper","name":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","route":"/key-papers/paper-robin-jones-lancet-2016/"},{"id":"paper-robin-jones-ann-oncol-2018","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-robin-jones-ann-oncol-2018/"},{"id":"paper-esmo-sts-guideline-gronchi-ann-oncol-2021","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","route":"/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/"}]}}